Nucleophosmin mutations induce chemosensitivity in THP-1 leukemia cells by suppressing NF-κB activity and regulating Bax/Bcl-2 expression

Journal of Cancer

Volumn 7, Issue 15, 2016, Pages 2270-2279

  Zhang, Shuaishuai ^a   Qin, Fengxian ^b   Yang, Liyuan ^a   Xian, Jingrong ^a   Zou, Qin ^a   Jin, Hongjun ^a   Wang, Lu ^a   Zhang, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Liuzhou Worker Hospital   (China)

Author keywords

Acute myeloid leukemia; Bax; Bcl 2; Chemosensitivity; Gene mutation; NF B; Nucleophosmin

Indexed keywords

CYTARABINE; DAUNORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NUCLEOPHOSMIN; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; LUCIFERASE ASSAY; MONOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 85007007393     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.16010     Document Type: Article

References (44)

1. Okuwaki M. The structure and functions of NPM1/Nucleophsmin/B23.a multifunctional nucleolar acidic protein. Journal of biochemistry. 2008; 143(4):441-448.
2. Lindstrom MS. NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling. Biochem Res Int. 2011; 2011:195209.
3. Falini B,Mecucci C,Saglio G,et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica. 2008; 93(3):439-442.
4. Di Matteo A,Franceschini M,Chiarella S,et al. Molecules that target nucleophosmin for cancer treatment: an update. Oncotarget. 2016; 7(28): 44821-44840.
5. Falini B,Bolli N,Liso A,et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009; 23(10):1731-1743.
6. Falini B,Bolli N,Shan J,et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006; 107(11):4514-4523.
7. Falini B,Mecucci C,Tiacci E,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-266.
8. Falini B. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular.pathological.and clinical features. Cancer treatment and research. 2010; 145:149-168.
9. Haferlach C,Mecucci C,Schnittger S,et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic.pathologic.immunophenotypic.and prognostic features. Blood. 2009; 114(14):3024-3032.
10. Dohner K,Schlenk RF,Habdank M,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005; 106(12):3740-3746.
11. Schnittger S,Schoch C,Kern W,et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106(12):3733-3739.
12. Shahab S,Shamsi TS,Ahmed N. Prognostic Involvement of Nucleophosmin Mutations in Acute Myeloid Leaukemia. Asian Pacific Journal of Cancer Prevention. 2013; 14(10):5615-5620.
13. Becker H,Marcucci G,Maharry K,et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of clinical oncology. 2010; 28(4):596-604.
14. Razani B,Cheng G. NF-kappaB: much learned.much to learn. Science signaling. 2010; 3(138):pe29.
15. Klein U,Ghosh S. The Two Faces of NF-kappaB Signaling in Cancer Development and Therapy. Cancer cell. 2011; 20(5):556-558.
16. Tornatore L,Thotakura AK,Bennett J,et al. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends in cell biology. 2012; 22(11):557-566.
17. Guzman ML,Neering SJ,Upchurch D,et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001; 98(8):2301-2307.
18. Volk A,Li J,Xin J,et al. AML Cells Utilize TNF-Driven JNK Signaling As a Critical NF-κB-Independent Survival Signal. Blood. 2013; 122: 2890.
19. Jacamo R,Chen Y,Wang Z,et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood. 2014; 123(17):2691-2702.
20. Turco MC,Romano MF,Petrella A,et al. NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia. 2004; 18(1):11-17.
21. Gupta SC,Sundaram C,Reuter S,et al. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochimica et biophysica acta. 2010; 1799(10-12):775-787.
22. Haruki K,Shiba H,Fujiwara Y,et al. Inhibition of nuclear factor-kappaB enhances the antitumor effect of tumor necrosis factor-alpha gene therapy for hepatocellular carcinoma in mice. Surgery. 2013; 154(3):468-478.
23. Braun T,Carvalho G,Fabre C,et al. Targeting NF-kappaB in hematologic malignancies. Cell death and differentiation. 2006; 13(5):748-758.
24. Stark LA,Dunlop MG. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Molecular and cellular biology. 2005; 25(14):5985-6004.
25. Yang YI,Ahn JH,Lee KT,et al. RSF1 is a positive regulator of NF-kappaB-induced gene expression required for ovarian cancer chemoresistance. Cancer research. 2014; 74(8):2258-2269.
26. Qu Y,Qu B,Wang X,et al. Knockdown of NF-kappaB p65 subunit expression suppresses growth of nude mouse lung tumour cell xenografts by inhibition of Bcl-2 apoptotic pathway. Cell biochemistry and function. 2015; 33(5):320-325.
27. Ortiz-Lazareno PC,Bravo-Cuellar A,Lerma-Diaz JM,et al. Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss. Cancer cell international. 2014; 14(1):13.
28. Cerami E,Gao J,Dogrusoz U,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.
29. Gao J,Aksoy Bü A,Dogrusoz U,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science signaling. 2013; 6(269):pl1.
30. Lee RE,Walker SR,Savery K,et al. Fold change of nuclear NF-kappaB determines TNF-induced transcription in single cells. Molecular cell. 2014; 53(6):867-879.
31. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008; 111(7):3322-3330.
32. Brinkmann K,Kashkar H. Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell death & disease. 2014; 5(3):e1098.
33. Burnett A,Wetzler M,Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011; 29(5):487-494.
34. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program. 2008:1-11.
35. Falini B,Sportoletti P,Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis.prognosis and therapeutic perspectives. Current opinion in oncology. 2009; 21(6):573-581.
36. Huang M,Thomas D,Li MX,et al. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 2013; 27(10):1970-1980.
37. Dhar SK,Lynn BC,Daosukho C,et al. Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. The Journal of biological chemistry. 2004; 279(27):28209-28219.
38. Leong SM,Tan BX,Bte Ahmad B,et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood. 2010; 116(17):3286-3296.
39. Sarosiek KA,Ni Chonghaile T,Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends in cell biology. 2013; 23(12):612-619.
40. Yinjun L,Jie J,Yungui W. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leukemia research. 2005; 29(1):99-105.
41. Bradbury DA,Zhu YM,Russell NH,et al. Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leukemia Lymphoma. 1997; 24(3-4):221-228.
42. Ong YL,McMullin MF,Bailie KE,et al. High bax expression is a good prognostic indicator in acute myeloid leukaemia. British journal of haematology. 2000; 111(1):182-189.
43. Del Poeta G,Ammatuna E,Lavorgna S,et al. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. British journal of haematology. 2010; 149(3):383-387.
44. Greiner J,Ono Y,Hofmann S,et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood. 2012; 120(6):1282-1289.